The value of pretreatment serum butyrylcholinesterase level as a novel prognostic biomarker in patients with cervical cancer treated with primary (chemo-)radiation therapy.
Die prognostische Bedeutung prätherapeutischer Butyrylcholinesterase-Serumspiegel in Zervixkarzinompatientinnen unter primärer (Chemo‑)Radiotherapie.
Cervix cancer
Cholinesterase
Prognosis
Survival
Treatment response
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
12
09
2018
accepted:
11
01
2019
pubmed:
10
2
2019
medline:
22
1
2020
entrez:
10
2
2019
Statut:
ppublish
Résumé
Deficiency in butyrylcholinesterase (BChE), a condition commonly noticed in liver damage, inflammation, and malnutrition, has previously been associated with impaired prognosis in different malignancies. The aim of the present study was to investigate the value of pretreatment serum BChE levels as a prognostic biomarker in patients with cervical cancer treated with primary (chemotherapy-[chemo-])radiation therapy. We retrospectively evaluated data of a consecutive series of patients with cervical cancer treated with primary (chemo-)radiation therapy between 1998 and 2015. Pretreatment serum BChE levels were correlated with clinico-pathological parameters and response to treatment. Uni- and multivariate survival analyses were performed to assess the association between decreased serum BChE levels and progression-free (PFS), cancer-specific (CSS), and overall survival (OS). A total of 356 patients were eligible for inclusion into the present study. The median (IQR) pretreatment serum BChE level was 6180 (4990-7710) IU/l. Lower serum BChE levels were associated with lower BMI (p < 0.001), advanced tumor stage (p = 0.04), poor treatment response (p = 0.002), the occurrence of disease recurrence (p = 0.003), and the risk of death (p < 0.001). In uni- and multivariate analyses, low pretreatment serum BChE levels were independently associated with shorter PFS (HR 1.8 [1.2-2.6]; p = 0.002), CSS (HR 2.2 [1.4-3.5], p < 0.001), and OS (HR 2.0 [1.4-2.9]; p < 0.001). Low pretreatment serum BChE levels are associated with advanced tumor stage and poor response to treatment, and serve as an independent prognostic biomarker for shorter PFS, CSS, and OS in patients with cervical cancer treated with primary (chemo-)radiation therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Deficiency in butyrylcholinesterase (BChE), a condition commonly noticed in liver damage, inflammation, and malnutrition, has previously been associated with impaired prognosis in different malignancies. The aim of the present study was to investigate the value of pretreatment serum BChE levels as a prognostic biomarker in patients with cervical cancer treated with primary (chemotherapy-[chemo-])radiation therapy.
METHODS
METHODS
We retrospectively evaluated data of a consecutive series of patients with cervical cancer treated with primary (chemo-)radiation therapy between 1998 and 2015. Pretreatment serum BChE levels were correlated with clinico-pathological parameters and response to treatment. Uni- and multivariate survival analyses were performed to assess the association between decreased serum BChE levels and progression-free (PFS), cancer-specific (CSS), and overall survival (OS).
RESULTS
RESULTS
A total of 356 patients were eligible for inclusion into the present study. The median (IQR) pretreatment serum BChE level was 6180 (4990-7710) IU/l. Lower serum BChE levels were associated with lower BMI (p < 0.001), advanced tumor stage (p = 0.04), poor treatment response (p = 0.002), the occurrence of disease recurrence (p = 0.003), and the risk of death (p < 0.001). In uni- and multivariate analyses, low pretreatment serum BChE levels were independently associated with shorter PFS (HR 1.8 [1.2-2.6]; p = 0.002), CSS (HR 2.2 [1.4-3.5], p < 0.001), and OS (HR 2.0 [1.4-2.9]; p < 0.001).
CONCLUSIONS
CONCLUSIONS
Low pretreatment serum BChE levels are associated with advanced tumor stage and poor response to treatment, and serve as an independent prognostic biomarker for shorter PFS, CSS, and OS in patients with cervical cancer treated with primary (chemo-)radiation therapy.
Identifiants
pubmed: 30737542
doi: 10.1007/s00066-019-01430-z
pii: 10.1007/s00066-019-01430-z
pmc: PMC6488555
doi:
Substances chimiques
Biomarkers
0
Butyrylcholinesterase
EC 3.1.1.8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
430-440Références
Coll Antropol. 2000 Dec;24(2):373-80
pubmed: 11216405
J Clin Oncol. 2002 Feb 15;20(4):966-72
pubmed: 11844818
Life Sci. 2003 Mar 28;72(18-19):2159-68
pubmed: 12628474
J Am Diet Assoc. 2004 Aug;104(8):1258-64
pubmed: 15281044
Rom J Intern Med. 2002;40(1-4):43-51
pubmed: 15526539
World J Gastroenterol. 2005 Aug 7;11(29):4604-6
pubmed: 16052698
Nutrition. 2006 Apr;22(4):355-60
pubmed: 16413750
Toxicology. 2007 Apr 20;233(1-3):60-9
pubmed: 17194517
Radiother Oncol. 2007 May;83(2):148-55
pubmed: 17531904
Gynecol Oncol. 2007 Oct;107(1):114-7
pubmed: 17617445
J Cancer Res Ther. 2008 Jan-Mar;4(1):21-5
pubmed: 18417898
Br J Pharmacol. 2008 Aug;154(8):1558-71
pubmed: 18500366
Eur J Clin Pharmacol. 2008 Sep;64(9):895-900
pubmed: 18506436
J Clin Oncol. 2008 Dec 10;26(35):5802-12
pubmed: 19001332
Int J Cancer. 2009 Mar 1;124(5):1090-6
pubmed: 19048619
N Engl J Med. 2009 Apr 2;360(14):1385-94
pubmed: 19339719
Int J Gynaecol Obstet. 2009 May;105(2):107-8
pubmed: 19342051
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
Int J Gynecol Cancer. 2010 Aug;20(6):1052-7
pubmed: 20683416
AANA J. 2010 Aug;78(4):313-20
pubmed: 20879632
Radiother Oncol. 2011 Jul;100(1):116-23
pubmed: 21821305
Gynecol Oncol. 1990 Sep;38(3):352-7
pubmed: 2227547
Ann Hepatol. 2012 May-Jun;11(3):356-63
pubmed: 22481455
Br J Cancer. 2012 Sep 4;107(6):918-24
pubmed: 22871885
Australas Med J. 2011;4(7):374-8
pubmed: 23393522
ScientificWorldJournal. 2014 Mar 04;2014:948305
pubmed: 24741368
Nat Rev Cancer. 2014 Nov;14(11):754-62
pubmed: 25291291
Strahlenther Onkol. 2015 May;191(5):421-8
pubmed: 25413986
J Clin Oncol. 2015 Jul 1;33(19):2136-42
pubmed: 25732170
Int J Clin Exp Pathol. 2015 May 01;8(5):5273-81
pubmed: 26191228
Int J Clin Oncol. 2016 Apr;21(2):379-383
pubmed: 26223693
Oncotarget. 2016 Mar 22;7(12):15230-42
pubmed: 26885692
Radiother Oncol. 2016 Sep;120(3):428-433
pubmed: 27134181
Int Urol Nephrol. 2016 Dec;48(12):1993-1999
pubmed: 27554671
Oncotarget. 2016 Nov 15;7(46):74886-74894
pubmed: 27713124
Oncotarget. 2017 Feb 21;8(8):13400-13412
pubmed: 28077792
Oncotarget. 2017 Apr 11;8(15):24327-24336
pubmed: 28212582
Strahlenther Onkol. 2017 Jul;193(7):543-551
pubmed: 28492995
Strahlenther Onkol. 2017 Dec;193(12):1048-1055
pubmed: 28660291
Oncotarget. 2017 Apr 16;8(46):81250-81260
pubmed: 29113384
Strahlenther Onkol. 2018 May;194(5):403-413
pubmed: 29322205
Gynecol Oncol. 1995 Aug;58(2):157-8
pubmed: 7622099
Anaesthesia. 1997 Mar;52(3):244-60
pubmed: 9124666